These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37770770)

  • 1. Efficacy and Safety of Single-Pill Combination of Rosuvastatin and Ezetimibe in Chinese Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Treatment (ROZEL): A Randomized, Double-Blind, Double Dummy, Active-Controlled Phase 3 Clinical Trial.
    Su Q; Liu Y; Zhang G; Xu L; Wang M; Mei S; Garon G; Wu Y; Lv Q; Ma C
    Adv Ther; 2023 Dec; 40(12):5285-5299. PubMed ID: 37770770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ezetimibe and Rosuvastatin Combination Treatment Can Reduce the Dose of Rosuvastatin Without Compromising Its Lipid-lowering Efficacy.
    Rhee MY; Kim KJ; Kim SH; Yoon YW; Rha SW; Hong SJ; Kwak CH; Kim W; Nam CW; Park TH; Hong TJ; Park S; Ahn Y; Lee N; Jeon HK; Jeon DW; Han KR; Moon KW; Chae IH; Kim HY; Kim HS
    Clin Ther; 2019 Dec; 41(12):2571-2592. PubMed ID: 31727361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 3 Randomized Controlled Trial to Evaluate Efficacy and Safety of New-Formulation Zenon (Rosuvastatin/Ezetimibe Fixed-Dose Combination) in Primary Hypercholesterolemia Inadequately Controlled by Statins.
    Catapano AL; Vrablik M; Karpov Y; Berthou B; Loy M; Baccara-Dinet M
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484221138284. PubMed ID: 36420979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial.
    Hong SJ; Jeong HS; Ahn JC; Cha DH; Won KH; Kim W; Cho SK; Kim SY; Yoo BS; Sung KC; Rha SW; Shin JH; Han KR; Chung WS; Hyon MS; Lee HC; Bae JH; Rhee MY; Kwan J; Jeon DW; Yoo KD; Kim HS
    Clin Ther; 2018 Feb; 40(2):226-241.e4. PubMed ID: 29402522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Fixed-dose Combination of Low-intensity Rosuvastatin and Ezetimibe Versus Moderate-intensity Rosuvastatin Monotherapy on Lipid Profiles in Patients With Hypercholesterolemia: A Randomized, Double-blind, Multicenter, Phase III Study.
    Lee SA; Kim W; Hong TJ; Ahn Y; Kim MH; Hong SJ; Kim BS; Kim SY; Chae IH; Kim BJ; Rhee MY; Shin JH; Kang TS; Cho JM; Kim JS; Lee CW
    Clin Ther; 2021 Sep; 43(9):1573-1589. PubMed ID: 34429197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial.
    Obońska K; Kasprzak M; Sikora J; Obońska E; Racki K; Goździkiewicz N; Krintus M; Kubica J
    Trials; 2017 Jul; 18(1):316. PubMed ID: 28697767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
    Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
    JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe.
    Yamazaki D; Ishida M; Watanabe H; Nobori K; Oguma Y; Terata Y; Koyama T; Iino K; Kosaka T; Ito H
    Lipids Health Dis; 2013 Feb; 12():9. PubMed ID: 23374898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe).
    Kim KJ; Kim SH; Yoon YW; Rha SW; Hong SJ; Kwak CH; Kim W; Nam CW; Rhee MY; Park TH; Hong TJ; Park S; Ahn Y; Lee N; Jeon HK; Jeon DW; Han KR; Moon KW; Chae IH; Kim HS
    Cardiovasc Ther; 2016 Oct; 34(5):371-82. PubMed ID: 27506635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
    Farnier M; Jones P; Severance R; Averna M; Steinhagen-Thiessen E; Colhoun HM; Du Y; Hanotin C; Donahue S
    Atherosclerosis; 2016 Jan; 244():138-46. PubMed ID: 26638010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
    Ballantyne CM; Laufs U; Ray KK; Leiter LA; Bays HE; Goldberg AC; Stroes ES; MacDougall D; Zhao X; Catapano AL
    Eur J Prev Cardiol; 2020 Apr; 27(6):593-603. PubMed ID: 31357887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination Therapy of Rosuvastatin and Ezetimibe in Patients with High Cardiovascular Risk.
    Yang YJ; Lee SH; Kim BS; Cho YK; Cho HJ; Cho KI; Kim SY; Ryu JK; Cho JM; Park JI; Park JS; Park CG; Chun WJ; Kim MA; Jin DK; Lee N; Kim BJ; Koh KK; Suh J; Lee SH; Lee BK; Oh SJ; Jin HY; Ahn Y; Lee SG; Bae JH; Park WJ; Lee SC; Lee HC; Lee J; Park C; Lee B; Jang Y
    Clin Ther; 2017 Jan; 39(1):107-117. PubMed ID: 28007331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial.
    Cannon CP; Cariou B; Blom D; McKenney JM; Lorenzato C; Pordy R; Chaudhari U; Colhoun HM;
    Eur Heart J; 2015 May; 36(19):1186-94. PubMed ID: 25687353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey.
    Krempf M; Simpson RJ; Ramey DR; Brudi P; Giezek H; Tomassini JE; Lee R; Farnier M
    Lipids Health Dis; 2015 May; 14():45. PubMed ID: 25985907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Ezetimibe and Rosuvastatin Combination Therapy Versus Those of Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia.
    Kim W; Yoon YE; Shin SH; Bae JW; Hong BK; Hong SJ; Sung KC; Han SH; Kim W; Rhee MY; Kim SH; Lee SE; Hyon MS; Hwang GS; Son JW; Kim JY; Kim MK; Kim SW; Park JH; Shin JH; Park CG
    Clin Ther; 2018 Jun; 40(6):993-1013. PubMed ID: 29857919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.
    Ambegaonkar BM; Tipping D; Polis AB; Tomassini JE; Tershakovec AM
    Atherosclerosis; 2014 Dec; 237(2):829-37. PubMed ID: 25463129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of rosuvastatin versus atorvastatin in high-risk Chinese patients with hypercholesterolemia: a randomized, double-blind, active-controlled study.
    Zhao S; Peng D
    Curr Med Res Opin; 2018 Feb; 34(2):227-235. PubMed ID: 28836458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature.
    Yu M; Liang C; Kong Q; Wang Y; Li M
    Lipids Health Dis; 2020 Jan; 19(1):1. PubMed ID: 31900179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Dyslipidemia Control by Combination Therapy with Rosuvastatin 10 Mg and Ezetimibe 10 Mg Compared with Rosuvastatin 20 Mg Monotherapy in Patients with Chronic Coronary Syndromes: A Randomized, Single-blind Controlled Trial.
    Tran AV; Tran BLT; Bui NM; Le ATT; Nguyen DT; Tran SK; Ngo TH
    Cardiovasc Hematol Agents Med Chem; 2024; 22(3):390-398. PubMed ID: 38275031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
    Nissen SE; Stroes E; Dent-Acosta RE; Rosenson RS; Lehman SJ; Sattar N; Preiss D; Bruckert E; Ceška R; Lepor N; Ballantyne CM; Gouni-Berthold I; Elliott M; Brennan DM; Wasserman SM; Somaratne R; Scott R; Stein EA;
    JAMA; 2016 Apr; 315(15):1580-90. PubMed ID: 27039291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.